ATE352618T1 - Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält - Google Patents

Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält

Info

Publication number
ATE352618T1
ATE352618T1 AT98912966T AT98912966T ATE352618T1 AT E352618 T1 ATE352618 T1 AT E352618T1 AT 98912966 T AT98912966 T AT 98912966T AT 98912966 T AT98912966 T AT 98912966T AT E352618 T1 ATE352618 T1 AT E352618T1
Authority
AT
Austria
Prior art keywords
receptor
cell death
proteins
domain responsible
antagonists
Prior art date
Application number
AT98912966T
Other languages
English (en)
Inventor
Jian Ni
Reiner L Gentz
Guo-Liang Yu
Jeffrey Y Su
Craig A Rosen
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26717514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE352618(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Application granted granted Critical
Publication of ATE352618T1 publication Critical patent/ATE352618T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
AT98912966T 1997-03-17 1998-03-17 Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält ATE352618T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4084697P 1997-03-17 1997-03-17
US5402197P 1997-07-29 1997-07-29

Publications (1)

Publication Number Publication Date
ATE352618T1 true ATE352618T1 (de) 2007-02-15

Family

ID=26717514

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98912966T ATE352618T1 (de) 1997-03-17 1998-03-17 Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält

Country Status (14)

Country Link
US (2) US7803615B1 (de)
EP (1) EP0970213B1 (de)
JP (2) JP4330180B2 (de)
KR (1) KR100527638B1 (de)
CN (2) CN1624128A (de)
AT (1) ATE352618T1 (de)
AU (1) AU747635B2 (de)
CA (2) CA2644454A1 (de)
DE (1) DE69836956T2 (de)
DK (1) DK0970213T3 (de)
ES (1) ES2281126T3 (de)
NZ (2) NZ337795A (de)
PT (1) PT970213E (de)
WO (1) WO1998041629A2 (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
EP1012274B2 (de) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US7528239B1 (en) * 1997-02-13 2009-05-05 Immunex Corporation Receptor that binds trail
US6872568B1 (en) * 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
DE69836956T2 (de) 1997-03-17 2007-10-31 Human Genome Sciences, Inc. Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
EP1860187B1 (de) * 1997-05-15 2011-07-13 Genentech, Inc. Apo-2-Rezeptor
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
WO1999012963A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. Cysteine rich receptors: trail
ATE443723T1 (de) * 1998-06-12 2009-10-15 Genentech Inc Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
AU4817200A (en) * 1999-05-04 2000-11-17 Human Genome Sciences, Inc. Death domain containing receptor 5
JP2003507064A (ja) * 1999-08-25 2003-02-25 ゲノム セラピューティックス コーポレーション 膜結合タンパク質単離用膜貫通トラップ
BR0108187A (pt) * 2000-02-11 2005-04-05 Inst Genetics Llc Moléculas trade e usos relacionados com as mesmas
AU2048501A (en) 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
ATE415978T1 (de) 2000-07-27 2008-12-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
AU2002256895B2 (en) 2001-05-18 2008-09-18 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
PT1409544E (pt) 2001-07-03 2009-09-16 Genentech Inc Anticorpos de dr4 humanos e suas utilizações
WO2003011318A1 (en) * 2001-08-01 2003-02-13 Genset S.A. Agonists and antagonists of famoset for use in the treatment of metabolic disorders
WO2003029420A2 (en) 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
EP1439225A4 (de) 2001-10-04 2005-10-26 Kansai Tech Licensing Org Co Dr5-gen-promotor und siah-1-gen-promotor
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
EP1450847B1 (de) 2001-11-13 2010-09-29 Genentech, Inc. Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
EP1465925A4 (de) * 2001-12-20 2006-02-08 Human Genome Sciences Inc "antikörper, die sich immunspezifisch an trail?rezeptoren binden"
WO2003106974A2 (en) * 2002-06-18 2003-12-24 Irm Llc Diagnosis and treatment of chemoresistant tumors
EP2500032A1 (de) 2002-06-24 2012-09-19 Genentech, Inc. APO-2-Liganden-/Trailvarianten und Verwendungen dafür
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
RU2410438C2 (ru) * 2004-08-06 2011-01-27 Дженентек, Инк. Анализы и способы, использующие биомаркеры
DE602005027848D1 (de) 2004-08-06 2011-06-16 Genentech Inc Tests und verfahren unter verwendung von biomarkern
US20090175854A1 (en) * 2004-09-08 2009-07-09 Genentech, Inc. Methods of using death receptor ligands and CD20 antibodies
JP2008513367A (ja) * 2004-09-08 2008-05-01 ジェネンテック・インコーポレーテッド デスレセプターリガンド及びｃｄ２０抗体の使用方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
WO2006083937A2 (en) 2005-02-02 2006-08-10 The Uab Research Foundation Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists
AU2006279618A1 (en) * 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
PE20071101A1 (es) * 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
CA2626082C (en) 2005-10-13 2017-04-11 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
WO2010042890A2 (en) 2008-10-10 2010-04-15 Anaphore, Inc. Polypeptides that bind trail-ri and trail-r2
CA2749512A1 (en) * 2009-04-03 2010-10-07 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Antigenic determinants recognized by anti-human death receptor dr5 monoclonal antibody ad5-10, derivatives and use thereof
CA2773428A1 (en) * 2009-09-10 2011-03-17 Lonza Biologics Plc Method and system for polypeptide purification
WO2011057099A2 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
NZ610153A (en) 2010-10-29 2014-07-25 Daiichi Sankyo Co Ltd Novel anti-dr5 antibody
AR084141A1 (es) 2010-11-19 2013-04-24 Imai Toshio Anticuerpos neutralizadores anti-ccl20
WO2012117336A2 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Per La Salute Della Donna E Del Bambino Apoptosis-inducing molecules and uses therefor
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
PT2970473T (pt) 2013-03-14 2017-10-26 Bristol Myers Squibb Co Combinação de agonista de dr5 e antagonista anti-pd-1 e métodos de utilização
ES2623260T3 (es) 2013-03-22 2017-07-10 Koninklijke Philips N.V. Dispositivo para el tratamiento no invasivo de la piel usando luz laser
CN104693308B (zh) * 2013-12-05 2020-08-04 同济大学 感受胞内pH变化的Smad5蛋白及其应用
EP3323428A1 (de) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selektive c-flip-hemmer als antikrebsmittel
CN108997503B (zh) * 2017-06-06 2021-07-23 深圳市中科艾深医药有限公司 人sDR5-Fc重组融合蛋白及其作为制备治疗生殖系统炎症的药物中的应用
EP3910331A1 (de) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intrazelluläre kinase in verbindung mit resistenz gegen t-zell-vermittelte zytotoxizität und verwendungen davon
EP4257132A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
EP0510691B1 (de) * 1991-04-26 2004-11-03 Osaka Bioscience Institute Für ein menschliches Zelloberflächen-Antigen kodierende DNS
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
KR100510234B1 (ko) * 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
EP1012274B2 (de) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. "death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20020160446A1 (en) 2000-11-14 2002-10-31 Holtzman Douglas A. Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
US20010010924A1 (en) * 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
DE69836956T2 (de) 1997-03-17 2007-10-31 Human Genome Sciences, Inc. Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
EP1007562A4 (de) 1997-04-16 2000-09-27 Millennium Pharm Inc Tomornekrosefaktorrezeptor verwandte proteine tango-63d und tango-63e
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP1860187B1 (de) * 1997-05-15 2011-07-13 Genentech, Inc. Apo-2-Rezeptor
JP2002508663A (ja) 1997-06-18 2002-03-19 ジェネンテク，インコーポレイテッド Ａｐｏ−２ＤｃＲ
AU756759B2 (en) 1997-06-26 2003-01-23 Immunex Corporation Protein that binds trail
PT1181319E (pt) 1999-05-28 2009-07-14 Genentech Inc Anticorpos quiméricos contra dr4 e suas utilizações
ZA200002867B (en) 1999-06-09 2001-12-07 Pfizer Prod Inc Process for preparing sertraline from chiral tetralone.
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Also Published As

Publication number Publication date
CA2285040C (en) 2009-01-27
KR20000076364A (ko) 2000-12-26
JP4330180B2 (ja) 2009-09-16
JP2001520513A (ja) 2001-10-30
PT970213E (pt) 2007-04-30
US20020098550A1 (en) 2002-07-25
CA2285040A1 (en) 1998-09-24
CN1624128A (zh) 2005-06-08
JP2008081503A (ja) 2008-04-10
DE69836956D1 (de) 2007-03-15
DE69836956T2 (de) 2007-10-31
EP0970213B1 (de) 2007-01-24
KR100527638B1 (ko) 2005-11-23
US7803615B1 (en) 2010-09-28
CN1275162A (zh) 2000-11-29
NZ508381A (en) 2002-09-27
NZ337795A (en) 2001-06-29
EP0970213A2 (de) 2000-01-12
ES2281126T3 (es) 2007-09-16
CA2644454A1 (en) 1998-09-24
AU747635B2 (en) 2002-05-16
CN1184315C (zh) 2005-01-12
WO1998041629A2 (en) 1998-09-24
HK1025352A1 (en) 2000-11-10
DK0970213T3 (da) 2007-05-21
AU6763598A (en) 1998-10-12
WO1998041629A3 (en) 1998-10-29

Similar Documents

Publication Publication Date Title
DE69836956D1 (de) Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
DE69834027D1 (de) Tumor-nekrose-faktor rezeptor 5
AU6250098A (en) Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
DE69837996D1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
DE69841140D1 (de) Interleukin-17 rezeptor-ähnliches protein
WO2001055205A8 (en) Nucleic acids, proteins, and antibodies
WO2000066156A8 (en) Death domain containing receptor 5
WO2001054472A3 (en) Nucleic acids, proteins, and antibodies
WO1999035262A3 (en) Apoptosis inducing molecule ii
WO2001055306A8 (en) Nucleic acids, proteins, and antibodies
EP1003767A4 (de) Menschlicher tumornekrosefaktor-rezeptor tr10
EP1178828A4 (de) "death-domain"enthaltender rezeptor
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
ATE472599T1 (de) Chemokin alpha-5
WO1998027932A3 (en) Cerebellum and embryo specific protein
DE60027563D1 (de) Fc-Fusionsproteine des MENSCHLICHEN TUMOR-NEKROSE-FAKTOR-Rezeptors TR10
WO2001005834A9 (en) Human tumor necrosis factor receptors tr13 and tr14
WO2002018622A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
WO2001055305A3 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0970213

Country of ref document: EP